FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to endocrinology, and can be used for treating type 2 diabetes that is ensured by introduction of effective amount of compound Cysteamine or its salts combined with metformin or insulin.
EFFECT: invention allows improving clinical effectiveness due to higher expression of glucose transporter and higher adiponectin level that increases insulin sensitivity.
7 tbl, 4 ex, 10 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MATERIALS AND METHODS FOR METABOLISM MODULATION | 2005 |
|
RU2387445C2 |
| METHOD OF TREATING HYPERGLYCAEMIA | 2017 |
|
RU2739255C2 |
| COMBINATION FOR TREATMENT OF DIABETES AND COMPLICATIONS THEREOF | 2011 |
|
RU2451506C1 |
| METHOD OF WEIGHT REDUCTION | 2013 |
|
RU2664442C2 |
| APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
| METHODS OF DIACEREIN APPLICATION IN ADDITIONAL TREATMENT OF DIABETES | 2011 |
|
RU2563988C2 |
| COMPOSITIONS FOR PERORAL DELIVERY OF METFORMIN THROUGH MUCOUS MEMBRANES | 2006 |
|
RU2409357C2 |
| SYSTEM OF SEPARATE MEDICATION DELIVERY | 2002 |
|
RU2351317C2 |
| PHARMACEUTICAL COMBINATION, COMPOSITION, AND COMBINED COMPOSITION CONTAINING GLUCOKINASE ACTIVATOR AND BIGUANIDE HYPOGLYCEMIC DRUG, AS WELL AS THEIR PREPARATION METHOD, AND THEIR USE | 2019 |
|
RU2780377C2 |
| NOVEL VANADIUM DERIVATIVES HAVING HYPOGLYCEMIC ACTIVITY | 2019 |
|
RU2709491C1 |
